{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:14:27Z","timestamp":1751429667359,"version":"3.41.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-07263-4","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:44:48Z","timestamp":1751381088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A comparative study of GVHD prophylaxis using low dose ATG versus PTCy for PBSCT based on two independent prospective cohorts"],"prefix":"10.1038","volume":"15","author":[{"given":"Souichi","family":"Shiratori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kuroha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senji","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mine","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"7263_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1056\/NEJM199907013410103","volume":"341","author":"G Soci\u00e9","year":"1999","unstructured":"Soci\u00e9, G. et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late effects working committee of the international bone marrow transplant registry. N Engl. J. Med. 341, 14\u201321 (1999).","journal-title":"N Engl. J. Med."},{"key":"7263_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1749-6632.1999.tb08452.x","volume":"872","author":"SM Lanzkron","year":"1999","unstructured":"Lanzkron, S. M., Collector, M. I. & Sharkis, S. J. Homing of long-term and short-term engrafting cells in vivo. Ann. N Y Acad. Sci. 872, 48\u201354 (1999). discussion 54\u201356.","journal-title":"Ann. N Y Acad. Sci."},{"key":"7263_CR3","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti, C. et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl. J. Med. 367, 1487\u20131496 (2012).","journal-title":"N Engl. J. Med."},{"key":"7263_CR4","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1182\/blood.V98.10.2942","volume":"98","author":"A Bacigalupo","year":"2001","unstructured":"Bacigalupo, A. et al. Antithymocyte Globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98, 2942\u20132947 (2001).","journal-title":"Blood"},{"key":"7263_CR5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke, J. et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell Globulin in Haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 10, 855\u2013864 (2009).","journal-title":"Lancet Oncol."},{"key":"7263_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kr\u00f6ger","year":"2016","unstructured":"Kr\u00f6ger, N. et al. Antilymphocyte Globulin for prevention of chronic Graft-versus-Host disease. N Engl. J. Med. 374, 43\u201353 (2016).","journal-title":"N Engl. J. Med."},{"key":"7263_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","volume":"17","author":"I Walker","year":"2016","unstructured":"Walker, I., Panzarella, T. & Couban, S. Pretreatment with anti-thymocyte Globulin versus no anti-thymocyte Globulin in patients with haematological malignancies undergoing Haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 17, 164\u2013173 (2016).","journal-title":"Lancet Oncol."},{"key":"7263_CR8","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","volume":"35","author":"RJ Soiffer","year":"2017","unstructured":"Soiffer, R. J. et al. Prospective, randomized, Double-Blind, phase III clinical trial of Anti-T-Lymphocyte Globulin to assess impact on chronic Graft-Versus-Host Disease-Free survival in patients undergoing HLA-Matched unrelated myeloablative hematopoietic cell transplantation. J. Clin. Oncol. 35, 4003\u20134011 (2017).","journal-title":"J. Clin. Oncol."},{"key":"7263_CR9","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1200\/JCO.20.00150","volume":"38","author":"YJ Chang","year":"2020","unstructured":"Chang, Y. J. et al. Antithymocyte Globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, Open-Label, randomized controlled study. J. Clin. Oncol. 38, 3367\u20133376 (2020).","journal-title":"J. Clin. Oncol."},{"key":"7263_CR10","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","volume":"6","author":"AEC Broers","year":"2022","unstructured":"Broers, A. E. C. et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 6, 3378\u20133385 (2022).","journal-title":"Blood Adv."},{"key":"7263_CR11","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade, J. et al. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host disease prophylaxis. N Engl. J. Med. 388, 2338\u20132348 (2023).","journal-title":"N Engl. J. Med."},{"key":"7263_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41409-020-0985-3","volume":"56","author":"S Shiratori","year":"2021","unstructured":"Shiratori, S. et al. Low-dose anti-thymocyte Globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation. Bone Marrow Transpl. 56, 129\u2013136 (2021).","journal-title":"Bone Marrow Transpl."},{"key":"7263_CR13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41409-023-02162-6","volume":"59","author":"J Sugita","year":"2024","unstructured":"Sugita, J. et al. Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor. Bone Marrow Transpl. 59, 344\u2013349 (2024).","journal-title":"Bone Marrow Transpl."},{"key":"7263_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris, A. C. et al. International, multicenter standardization of acute Graft-versus-Host disease clinical data collection: A report from the Mount Sinai acute GVHD international consortium. Biol. Blood Marrow Transpl. 22, 4\u201310 (2016).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"7263_CR15","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich, A. H. et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol. Blood Marrow Transpl. 11, 945\u2013956 (2005).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"7263_CR16","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand, P. et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood 123, 3664\u20133671 (2014).","journal-title":"Blood"},{"key":"7263_CR17","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"SG Holtan","year":"2015","unstructured":"Holtan, S. G. et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 125, 1333\u20131338 (2015).","journal-title":"Blood"},{"key":"7263_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 48, 452\u2013458 (2013).","journal-title":"Bone Marrow Transpl."},{"key":"7263_CR19","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack, O. et al. Prophylaxis and management of graft versus host disease after Stem-Cell transplantation for haematological malignancies: updated consensus recommendations of the European society for blood and marrow transplantation. Lancet Haematol. 11, e147\u2013e159 (2024).","journal-title":"Lancet Haematol."},{"key":"7263_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41408-024-00990-3","volume":"14","author":"E Brissot","year":"2024","unstructured":"Brissot, E. et al. Post-transplant cyclophosphamide versus anti-thymocyte Globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10\/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial. Blood Cancer J. 14, 31 (2024).","journal-title":"Blood Cancer J."},{"key":"7263_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13045-020-00923-0","volume":"13","author":"E Brissot","year":"2020","unstructured":"Brissot, E. et al. Post-transplant cyclophosphamide versus antithymocyte Globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10\/10 HLA-matched unrelated donors. J. Hematol. Oncol. 13, 87 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"7263_CR22","doi-asserted-by":"publisher","first-page":"e21571","DOI":"10.1097\/MD.0000000000021571","volume":"99","author":"MW Lee","year":"2020","unstructured":"Lee, M. W. et al. A comparison of post-transplantation cyclophosphamide versus antithymocyte-globulin in patients with hematological malignancies undergoing HLA-matched unrelated donor transplantation. Med. (Baltim). 99, e21571 (2020).","journal-title":"Med. (Baltim)."},{"key":"7263_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/cncr.33255","volume":"127","author":"G Battipaglia","year":"2021","unstructured":"Battipaglia, G. et al. Post-transplantation cyclophosphamide versus antithymocyte Globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the acute leukemia working party of the European society for blood and marrow transplantation. Cancer 127, 209\u2013218 (2021).","journal-title":"Cancer"},{"key":"7263_CR24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/bjh.19031","volume":"203","author":"M Aydin","year":"2023","unstructured":"Aydin, M., de Leeuw, D. C. & Rutten, C. E. ATG versus PTCy in matched unrelated donor Haematopoietic stem cell transplantations with non-myeloablative conditioning. Br. J. Haematol. 203, 439\u2013445 (2023).","journal-title":"Br. J. Haematol."},{"key":"7263_CR25","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/s41375-024-02225-7","volume":"38","author":"O Penack","year":"2024","unstructured":"Penack, O. et al. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation? Leukemia 38, 1156\u20131163 (2024).","journal-title":"Leukemia"},{"key":"7263_CR26","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1182\/blood.2019000487","volume":"134","author":"G Battipaglia","year":"2019","unstructured":"Battipaglia, G. et al. Posttransplant cyclophosphamide vs antithymocyte Globulin in HLA-mismatched unrelated donor transplantation. Blood 134, 892\u2013899 (2019).","journal-title":"Blood"},{"key":"7263_CR27","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/bjh.13977","volume":"173","author":"RS Mehta","year":"2016","unstructured":"Mehta, R. S. et al. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor Haematopoietic cell transplantation. Br. J. Haematol. 173, 444\u2013455 (2016).","journal-title":"Br. J. Haematol."},{"key":"7263_CR28","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00277-019-03673-3","volume":"98","author":"Y Soltermann","year":"2019","unstructured":"Soltermann, Y. et al. Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study. Ann. Hematol. 98, 1485\u20131493 (2019).","journal-title":"Ann. Hematol."},{"key":"7263_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41409-019-0682-2","volume":"55","author":"C Nykolyszyn","year":"2020","unstructured":"Nykolyszyn, C. et al. Posttransplantation cyclophosphamide vs. antithymocyte Globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation. Bone Marrow Transpl. 55, 349\u2013355 (2020).","journal-title":"Bone Marrow Transpl."},{"key":"7263_CR30","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jtct.2021.06.018","volume":"27","author":"D Modi","year":"2021","unstructured":"Modi, D. et al. Post-transplant cyclophosphamide versus thymoglobulin in HLA-Mismatched unrelated donor transplant for acute myelogenous leukemia and myelodysplastic syndrome. Transpl. Cell. Ther. 27, 760\u2013767 (2021).","journal-title":"Transpl. Cell. Ther."},{"key":"7263_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-024-01032-8","volume":"14","author":"O Penack","year":"2024","unstructured":"Penack, O. et al. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation. Blood Cancer J. 14, 45 (2024).","journal-title":"Blood Cancer J."},{"key":"7263_CR32","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","volume":"3","author":"R Dul\u00e9ry","year":"2021","unstructured":"Dul\u00e9ry, R., Mohty, R. & Labopin, M. Early cardiac toxicity associated with Post-Transplant cyclophosphamide in allogeneic stem cell transplantation. JACC CardioOncol. 3, 250\u2013259 (2021).","journal-title":"JACC CardioOncol"},{"key":"7263_CR33","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1182\/bloodadvances.2022008792","volume":"7","author":"AI P\u00e9rez-Valencia","year":"2023","unstructured":"P\u00e9rez-Valencia, A. I. et al. Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant. Blood Adv. 7, 2018\u20132031 (2023).","journal-title":"Blood Adv."},{"key":"7263_CR34","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.bbmt.2008.05.023","volume":"14","author":"F Ayuk","year":"2008","unstructured":"Ayuk, F. et al. Comparison of two doses of antithymocyte Globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. Biol. Blood Marrow Transpl. 14, 913\u2013919 (2008).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"7263_CR35","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.bbmt.2009.07.006","volume":"15","author":"M Hamadani","year":"2009","unstructured":"Hamadani, M. et al. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte Globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biol. Blood Marrow Transpl. 15, 1422\u20131430 (2009).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"7263_CR36","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41409-017-0043-y","volume":"53","author":"R Devillier","year":"2018","unstructured":"Devillier, R. et al. Impact of antithymocyte Globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of bone marrow transplantation. Bone Marrow Transpl. 53, 431\u2013437 (2018).","journal-title":"Bone Marrow Transpl."},{"key":"7263_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.hemonc.2018.01.004","volume":"11","author":"C Boga","year":"2018","unstructured":"Boga, C. et al. Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine\/busulfan conditioning. Hematol. Oncol. Stem Cell. Ther. 11, 149\u2013157 (2018).","journal-title":"Hematol. Oncol. Stem Cell. Ther."},{"key":"7263_CR38","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00277-021-04521-z","volume":"100","author":"S Butera","year":"2021","unstructured":"Butera, S. et al. Impact of anti-thymocyte Globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience. Ann. Hematol. 100, 1837\u20131847 (2021).","journal-title":"Ann. Hematol."},{"key":"7263_CR39","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","volume":"7","author":"M Penack Ol, Marchetti","year":"2020","unstructured":"Penack Ol, Marchetti, M. et al. Prophylaxis and management of graft versus host disease after Stem-Cell transplantation for haematological malignancies: updated consensus recommendations of the European society for blood and marrow transplantation. Lancet Haematol. 7, e157\u2013e167 (2020).","journal-title":"Lancet Haematol."},{"key":"7263_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.trim.2017.11.001","volume":"46","author":"S Shiratori","year":"2018","unstructured":"Shiratori, S. et al. T-cell depletion effects of low-dose antithymocyte Globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation. Transpl. Immunol. 46, 21\u201322 (2018).","journal-title":"Transpl. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07263-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07263-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07263-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:44:50Z","timestamp":1751381090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07263-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7263"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07263-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TT reports grants from Sanofi and donations from SHIONOGI, during the conduct of the study. All the remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20677"}}